2-25240312-C-T
Variant summary
Our verdict is Pathogenic. The variant received 14 ACMG points: 14P and 0B. PM1PM5PP3_ModeratePP5_Very_Strong
The NM_022552.5(DNMT3A):c.2312G>A(p.Arg771Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000124 in 1,613,944 control chromosomes in the GnomAD database, with no homozygous occurrence. There is a variant allele frequency bias in the population database for this variant (GnomAdExome4), which may indicate mosaicism or somatic mutations in the reference population data. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R771G) has been classified as Likely pathogenic.
Frequency
Consequence
NM_022552.5 missense
Scores
Clinical Significance
Conservation
Publications
- Tatton-Brown-Rahman overgrowth syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Illumina, Ambry Genetics, ClinGen, G2P, Orphanet, Labcorp Genetics (formerly Invitae)
- Heyn-Sproul-Jackson syndromeInheritance: AD Classification: STRONG, MODERATE, LIMITED Submitted by: Ambry Genetics, ClinGen, G2P, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 14 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| DNMT3A | NM_022552.5 | c.2312G>A | p.Arg771Gln | missense_variant | Exon 19 of 23 | ENST00000321117.10 | NP_072046.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| DNMT3A | ENST00000321117.10 | c.2312G>A | p.Arg771Gln | missense_variant | Exon 19 of 23 | 1 | NM_022552.5 | ENSP00000324375.5 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152210Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.00000398 AC: 1AN: 251402 AF XY: 0.00000736 show subpopulations
GnomAD4 exome AF: 0.0000130 AC: 19AN: 1461734Hom.: 0 Cov.: 32 AF XY: 0.0000110 AC XY: 8AN XY: 727180 show subpopulations ⚠️ The allele balance in gnomAD version 4 Exomes is significantly skewed from the expected value of 0.5.
Age Distribution
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152210Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74364 show subpopulations ⚠️ The allele balance in gnomAD version 4 Genomes is significantly skewed from the expected value of 0.5.
ClinVar
Submissions by phenotype
Tatton-Brown-Rahman overgrowth syndrome Pathogenic:3
The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: <0.001%). Predicted Consequence/Location: Missense variant In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.90; 3Cnet: 0.92). Same nucleotide change resulting in same amino acid change has been previously reported to be associated with DNMT3A related disorder (ClinVar ID: VCV000438287 /PMID: 27701732). The variant has been reported to co-segregate with the disease in at least 3 similarly affected relatives/individuals in the same family or similarly affected unrelated families (PMID: 27701732). A different missense change at the same codon (p.Arg771Gly) has been reported to be associated with DNMT3A related disorder (ClinVar ID: VCV001709413). Therefore, this variant is classified as Likely pathogenic according to the recommendation of ACMG/AMP guideline.
Inborn genetic diseases Pathogenic:1
Acute myeloid leukemia;C4014545:Tatton-Brown-Rahman overgrowth syndrome;C5231475:Heyn-Sproul-Jackson syndrome Pathogenic:1
Absent from controls (or at extremely low frequency if recessive) in Genome Aggregation Database, Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium.;Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc).;The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls.;Assumed de novo, but without confirmation of paternity and maternity.;Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at